K-REACH Revision Lowers VMS Limits in Silicone Sealants (MFDS, 2026)

On May 3, 2026, the Korean Ministry of Food and Drug Safety (MFDS) published Notice No. 2026-11, amending K-REACH to lower the combined limit for volatile methyl siloxanes (VMS)—specifically D4 (octamethylcyclotetrasiloxane) and D5 (decamethylcyclopentasiloxane)—in silicone sealants from 500 ppm to 350 ppm. Enforcement begins October 1, 2026. This update directly affects manufacturers and exporters supplying silicone sealants to high-sensitivity sectors in South Korea, including architectural curtain wall systems and medical device encapsulation.

Event Overview

The MFDS issued K-REACH Amendment Notice No. 2026-11 on May 3, 2026. It revises the maximum allowable concentration of D4 and D5—measured as a combined total—in silicone sealants from 500 ppm to 350 ppm. The revised limit takes effect on October 1, 2026. No transitional provisions or grace periods beyond this date have been publicly announced.

Industries Affected by the Revision

Direct Exporters to South Korea

Companies exporting silicone sealants into South Korea must comply with the new limit by the enforcement date. Non-compliant batches risk rejection at customs or post-market regulatory action. Impact manifests in mandatory retesting, potential shipment delays, and increased documentation burden—including updated Safety Data Sheets (SDS) reflecting the revised VMS values.

Raw Material Suppliers

Suppliers of silicone polymers, fillers, or catalysts used in sealant formulation may face upstream requests for updated VMS test reports. Since D4/D5 often originate from polymer synthesis or residual solvents, suppliers must verify batch-specific VMS content—not just generic specifications—to support downstream compliance.

Sealant Formulators and Contract Manufacturers

Manufacturers blending raw materials into finished sealants are responsible for final product compliance. The 30% reduction necessitates reformulation adjustments or tighter control over incoming material quality. Process consistency, storage conditions (e.g., minimizing volatilization loss pre-testing), and analytical repeatability become critical.

Supply Chain & Regulatory Support Providers

Laboratories offering GC-MS testing for VMS must validate methods against the new 350 ppm threshold—particularly for low-concentration quantification accuracy and matrix interference in cured or uncured sealant samples. SDS authoring services will need updated toxicological references aligned with the revised exposure assumptions.

What Relevant Enterprises or Practitioners Should Focus On Now

Confirm testing capability alignment with the 350 ppm requirement

Exporters and formulators should verify whether their current GC-MS method validation covers reliable quantification down to ≤350 ppm in silicone sealant matrices. If not, method revalidation—or engagement with an accredited lab capable of meeting this sensitivity—is required before Q3 2026.

Review and update SDS entries for Section 3 (Composition) and Section 11 (Toxicological Information)

SDS revisions must reflect the new D4+D5 total concentration limit and any associated hazard communication updates per K-REACH Annex III requirements. Language and classification statements should align with MFDS guidance referenced in Notice No. 2026-11.

Map high-risk SK-bound product lines and prioritize testing

Identify which sealant SKUs are destined for architectural or medical applications in South Korea, as these fall under heightened scrutiny. Prioritize analytical testing for those SKUs first—especially if historical D4+D5 data is near or above 400 ppm—given the narrow margin to 350 ppm.

Monitor official MFDS communications for implementation clarifications

No supplementary guidance (e.g., sampling protocols, acceptable uncertainty thresholds, or exemptions for legacy stock) has been released as of May 2026. Stakeholders should subscribe to MFDS regulatory bulletins and track upcoming stakeholder consultations, if announced.

Editorial Perspective / Industry Observation

Observably, this revision signals a tightening of chemical controls in construction-related and healthcare-adjacent materials under K-REACH—not a standalone adjustment but part of a broader trend toward stricter VMS regulation in sensitive-use products across Asia. Analysis shows that the 30% cut reflects increasing regulatory attention on environmental persistence and potential endocrine activity of cyclic VMS, especially in indoor air and medical settings. From an industry perspective, it is more appropriately understood as a compliance milestone than a market-access barrier—provided testing and documentation readiness is achieved ahead of October 2026. Continued monitoring is warranted, as further reductions or expanded scope (e.g., to D6 or linear siloxanes) cannot be ruled out in future amendments.

This notice underscores how incremental regulatory updates—though technically narrow in scope—can trigger cross-functional actions across R&D, QA/QC, regulatory affairs, and supply chain management. Its significance lies less in novelty and more in execution discipline: verifying analytical readiness, updating technical documentation, and aligning internal processes with a fixed, non-negotiable deadline.

Information Sources

Primary source: Korean Ministry of Food and Drug Safety (MFDS), Notice No. 2026-11, published May 3, 2026. No additional guidance documents or FAQs have been issued as of the publication date. Pending clarification on enforcement interpretation—including sampling methodology and conformity assessment criteria—remains under observation.